The Australian Pesticides and Veterinary Medicines Authority (APVMA) is considering an application for registration of the products Numelvi 31.6 mg Tablets For Dogs, Numelvi 21.6 mg Tablets For Dogs, Numelvi 7.2 mg Tablets For Dogs and Numelvi 4.8 mg Tablets For Dogs (containing active constituent, atinvicitinib) for the symptomatic treatment of pruritus, inflammation, and clinical signs associated with allergic skin conditions, including atopic dermatitis in dogs.
We invite relevant written comment from 16 June to 16 July 2026 on whether registration of the products should be granted.
The APVMA is able to consider comments relating to the legislative grounds, including:
- chemistry and manufacture
- occupational health and safety
- public health
- environmental safety
- efficacy and target animal safety.
For more information see page 34, in the APVMA Gazette No 12, Tuesday 16 June 2026.
Please lodge your submission with a public submission coversheet. The coversheet provides options for how your submission will be published.
Please note that submissions will be published on the APVMA’s website unless you have asked for the submission to remain confidential. Note that all APVMA documents are subject to the access provisions of the Freedom of Information Act 1982 and may be required to be released under that Act should a request for access be made.
Please send your written submission by email or post to:
Case Management
Australian Pesticides and Veterinary Medicines Authority
GPO Box 574
Canberra ACT 2601, Australia
Email: casemanagement@apvma.gov.au